Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Lyon

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 21, 2022
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upJ Haanen, M Obeid, L Spain, et al.
ESMO Open|June 3, 2025
Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship careC Dauccia, E Agostinetto, L Arecco, et al.
Cell Death & Disease|May 8, 2015
Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosisL Roca-Alonso, L Castellano, A Mills, et al.
British Journal of Pharmacology|October 11, 2014
Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryM J Cross, B R Berridge, P J M Clements, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsG Curigliano, D Lenihan, M Fradley, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 31, 2022
European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatmentG A Lee, S Aktaa, E Baker, et al.
Gene Therapy|July 17, 2020
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIALA R Lyon, D Babalis, A C Morley-Smith, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 21, 2022
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upJ Haanen, M Obeid, L Spain, et al.
ESMO Open|June 3, 2025
Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship careC Dauccia, E Agostinetto, L Arecco, et al.
Cell Death & Disease|May 8, 2015
Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosisL Roca-Alonso, L Castellano, A Mills, et al.
British Journal of Pharmacology|October 11, 2014
Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryM J Cross, B R Berridge, P J M Clements, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsG Curigliano, D Lenihan, M Fradley, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 31, 2022
European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatmentG A Lee, S Aktaa, E Baker, et al.
Gene Therapy|July 17, 2020
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIALA R Lyon, D Babalis, A C Morley-Smith, et al.
Pageof 2